Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 611 publications
Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer.
Journal: JCI insight
Published: December 09, 2025
Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.
Journal: BMJ open
Published: December 08, 2025
Future directions for antibody-drug conjugates in urothelial cancer.
Journal: Expert review of anticancer therapy
Published: November 20, 2025
Reply to Jorge Esteban-Villarrubia and Guillermo De Velasco's Letter to the Editor re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4.
Journal: European urology
Published: November 18, 2025
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer.
Journal: JAMA oncology
Published: November 13, 2025
Nectin-4 in bladder cancer: biology and predictive biomarker potential.
Journal: Current opinion in urology
Published: November 03, 2025
Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making
Journal: Aktuelle Urologie
Published: October 23, 2025
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis.
Journal: European urology open science
Published: October 18, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.
Journal: European urology open science
Published: October 16, 2025
Harnessing genomic profiling for improved urothelial cancer outcomes.
Journal: Expert review of anticancer therapy
Published: October 15, 2025
Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
Journal: Journal of medical economics
Published: October 03, 2025
NECTIN4 amplification as a predictive biomarker for enfortumab vedotin response
Journal: Pathologie (Heidelberg, Germany)
Published: October 03, 2025
Last Updated: 01/07/2026